Mesa Laboratories, Inc. Stock

$86.42

4.31%

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US59064R1095

Symbol

MLAB

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Mesa Laboratories, Inc. Stock price

$86.42

-124.68 59.06% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-3.89 4.31%

ISIN

US59064R1095

Symbol

MLAB

Reports

Quarter | Annual

Index

NASDAQ Composite, S&P SmallCap 600

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$471.5m

Enterprise Value

$622.1m

Net debt

$150.6m

Cash

$27.3m

Shares outstanding

5.5m

Valuation (TTM | estimate)

P/E

negative | 48.3

P/S

2.0 | 1.8

EV/Sales

2.6 | 2.4

EV/FCF

14.7

P/B

3.0

Dividends

DPS

$0.64

Yield 1Y | 5Y

0.7% | 0.3%

Growth 1Y | 5Y

0.0% | 0.0%

Payout 1Y | 3Y

-177.8% | -4.1%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$241.0m | $256.5m

EBITDA

$32.8m | $63.7m

EBIT

$16.3m | $24.8m

Net Income

$-2.0m | $9.8m

Free Cash Flow

$42.3m

Growth (TTM | estimate)

Revenue

11.5% | 6.5%

EBITDA

38.3% | 94.0%

EBIT

563.5% | 51.7%

Net Income

99.2% | 595.4%

Free Cash Flow

1.8%

Financial Health

Equity Ratio

36.9%

Return on Equity

-1.2%

ROCE

6.1%

ROIC

-1.4%

Debt/Equity

1.1

EPS

$-0.4

FCF per Share

$7.7

Short interest

4.9%

Employees

736

Rev per Employee

$330.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Mesa Laboratories, Inc. Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a Mesa Laboratories, Inc. forecast:

7x Buy

70%

2x Hold

20%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a Mesa Laboratories, Inc. forecast:

Buy

70%

Hold

20%

Sell

10%

Analyst Estimates with Stock Price Targets

Financial data from Mesa Laboratories, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	241 241	11% 11% 100%
- Direct Costs	90 90	9% 9% 37%
Gross Profit	151 151	13% 13% 63%
- Selling and Administrative Expenses	99 99	9% 9% 41%
- Research and Development Expense	20 20	1% 1% 8%
EBITDA	33 33	38% 38% 14%
- Depreciation and Amortization	17 17	22% 22% 7%
EBIT (Operating Income) EBIT	16 16	564% 564% 7%
Net Profit	-1.97 -1.97	99% 99% -1%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Mesa Laboratories, Inc. Stock News

Neutral

GlobeNewsWire

●

11 days ago

MESA LABS DECLARES QUARTERLY DIVIDEND

LAKEWOOD, Colo., July 03, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025.

Neutral

GlobeNewsWire

●

12 days ago

Mesa Laboratories, Inc. to Announce First Quarter Results on August 5, 2025

LAKEWOOD, Colo., July 02, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the first quarter of fiscal year 2026 at approximately 8:00 A.M. Eastern time on Tuesday, August 5, 2025.

Neutral

GlobeNewsWire

●

about 2 months ago

Mesa Labs Announces Fourth Quarter and Full Fiscal Year 2025 Results

LAKEWOOD, Colo., May 28, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q25”) and full fiscal year (“FY25”) ended March 31, 2025 (amounts in thousands).

More Mesa Laboratories, Inc. News

Company Profile

Mesa Laboratories, Inc. engages in the design, manufacture, and marketing of instruments and disposable products utilized in healthcare, pharmaceutical, food, and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection, Instruments, Cold Chain Monitoring, and Cold Chain Packaging. The Sterilization and Disinfection segment offers testing services, along with the manufacturing and marketing of biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The Instrument segment manufactures and markets control instruments and disposable products. The Cold Chain Monitoring segment designs, develops, and markets systems which are used to monitor environmental parameters such as temperature, humidity, and differential pressure. The Cold Chain Packaging segment provides consulting services including compliance monitoring, packaging development, and validation or mapping of transport and storage containers, and thermal packaging products. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Head office	United States
CEO	Gary Owens
Employees	736
Founded	1982
Website	mesalabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now